9 February 2010

Medical Solutions' long march back

20/03/2002

Shares in fully-listed diagnostics and pharmaceuticals business Medical Solutions plunged from a high of nearly 200p to a 10.5p low as a brace of profit warnings and bad news scared investors away. Since Trevor Twose vacated the chief executive role, stand-in boss Charles Green is working hard to get the business back on track. William Davidson reports.

The straight-talking Green said: 'I am here to make sure 2002 is a good year. Despite the profit warnings, Medical Solutions is not out of control. In fact, it is generating cash, and out-of-control companies do not generate cash'.

The business is divided into two divisions: cancer diagnosis and pharmaceuticals. Green said these could eventually be split. And the vultures have been circling. 'I have had offers for bits of the business which were greater than the market cap of the entire company', he said. 'Even now, I could sell the group for two or three times its market cap. I could do that without getting out of bed'.

The main drivers behind the cancer diagnostic business are PathLore and Fairfield Imaging. PathLore is a locum service for pathologists - the people who diagnose which cells are cancerous and decide on treatment. Green said there is a critical shortage of trained pathologists in the UK, with around half of the 900 posts expected remain unfilled in the next two years. It means NHS pathologists are over-worked and often have to deal with cancer tests outside their area of expertise. PathLore enables NHS trusts to get the tests done quickly, and by the right people. It has the top 48 clinical pathologists on its books. Green said they can earn more in an hour's work using PathLore than they would in two days' of traditional work.

Its CellPath arm produces training equipment for cervical smear tests, an area which is notoriously inefficient. Of the 6.4 million smear tests carried out each year, more than nine per cent are incomplete. The NHS is testing CellPath's equipment as well as a competitors'. It will award the contract on a 70:30 basis between the two companies. Even if Medical Solutions was awarded only a 30 per cent slice of the pie, finance director Andy Longstaffe estimates it would be worth 'around £15 million per annum'.

In the year to December, sales rose 64 per cent to £16.1 million, while losses swelled from £1.21 million to £1.6 million. Since the results, the share price has picked up from 15p to 28p. If Green can perform the recovery he predicts, the shares could have a lot further to go.

Sector: Health Care Equipment & Services

Companies: Source BioScience

Subscribe today

Growth Company Investor is the leading magazine for investors in AIM and boasts award-winning research and analysis coverage. 
Subscribe now and receive a 50% discount

AIM in Review 2010

Growth Company Investor, in association with the London Stock Exchange, presents the most wide-ranging and detailed examination of the AIM market: AIM in Review 2010. For more information and to order, click here or contact our marketing team on 020 7250 7056.

Directors' Pay on AIM 2009 – ­ a Growth Company Investor publication in association with Deloitte

The report reveals the top-earning chief executives and remuneration levels at AIM's most profitable and fastest-growing companies. It also examines constituent parts, including basic salary, bonus, pensions, benefits and share-based payments. To order click here.

Free – Latest Stock Recommendations

Free access to the latest AIM stock recommendations and news from the award-winning Growth Company Investor team. Receive our tips on what stocks to buy direct to your inbox every Tuesday and Friday. Find out more today.

Select your level of risk and we select the funds

Cautious? Positive? Adventurous? Choose between three levels of risk for a fund of funds from Sharefunds, our sister company. Click here for more information.

The AIM Guide 2009/10

The brand new, fully updated AIM Guide 2009/2010 is now available to purchase. AIM Guide is the only fully comprehensive guide to AIM and is regarded as 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies.   Order your copy today and benefit from a £10 discount!

VCT Special Report 2009

This report's principal aim is to provide business owners seeking funding with information about the amount of funds that VCTs have to invest. Click here for more information.

Cash Shells Special Report 2009

Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy the Cash Shells 2009 Research Report today or email Halid Delkic to obtain a free two-page abstract.

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Aussie-listed Greenland Minerals & Energy wants to raise £20m and float on AIM

Mineral group plans £20m float 08/02/2010

Aussie-listed Greenland Minerals and Energy is planning a flotation on the London Stock Exchange to raise £20 million for a £1.4 billion world-class rare earth and uranium project at Kvanefjeld in Greenland.

Tags: Commodities , Fundraisings , New Issues

Sector: Mining

Randgold continues expansion 08/02/2010

African miner Randgold Resources plans hefty production and resource increases after lifting annual gold sales 27 per cent to £288 million. 

Tags: Commodities , Emerging markets , Full list , Growth Stocks

Sector: Mining

Companies: Randgold Resources

LED lighting pioneer moots AIM launch  08/02/2010

PhotonStar LED, which produces eco-friendly light bulbs with a claimed life of 11 years, is considering tapping AIM investors for around £5 million to fund acquisitions, says chief executive officer James Mckenzie

More News

Sectors

Vitesse Media Events